C12N 15/79
Vectors or expression systems specially adapted for eukaryotic hosts
C12N15/79 (Vectors or expression systems specially adapted for eukaryotic hosts) appears on 31,494 US grants and 47,113 published applications in this corpus.
Search patents in C12N- Granted patents
- 31,494
- Published applications
- 47,113
- Assignees
- 9,623
- Inventors
- 65,018
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 6 | 0 |
| 1984 | 6 | 0 |
| 1985 | 8 | 0 |
| 1986 | 16 | 0 |
| 1987 | 22 | 0 |
| 1988 | 42 | 0 |
| 1989 | 70 | 0 |
| 1990 | 74 | 0 |
| 1991 | 96 | 0 |
| 1992 | 140 | 0 |
| 1993 | 162 | 0 |
| 1994 | 176 | 0 |
| 1995 | 193 | 0 |
| 1996 | 381 | 0 |
| 1997 | 581 | 0 |
| 1998 | 822 | 0 |
| 1999 | 875 | 0 |
| 2000 | 762 | 0 |
| 2001 | 866 | 173 |
| 2002 | 760 | 1188 |
| 2003 | 770 | 1790 |
| 2004 | 641 | 1481 |
| 2005 | 514 | 1441 |
| 2006 | 784 | 1465 |
| 2007 | 801 | 1147 |
| 2008 | 635 | 1318 |
| 2009 | 731 | 1548 |
| 2010 | 905 | 1533 |
| 2011 | 857 | 1592 |
| 2012 | 893 | 1410 |
| 2013 | 823 | 1600 |
| 2014 | 1040 | 1823 |
| 2015 | 1295 | 1785 |
| 2016 | 1303 | 1733 |
| 2017 | 1377 | 1696 |
| 2018 | 1329 | 1786 |
| 2019 | 1359 | 2306 |
| 2020 | 1407 | 2353 |
| 2021 | 1416 | 2481 |
| 2022 | 1394 | 2689 |
| 2023 | 1287 | 2729 |
| 2024 | 1297 | 2963 |
| 2025 | 1464 | 2932 |
| 2026 | 1113 | 2151 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- Methods and materials for ameliorating creatine deficiency disorders6 Oct 2026US 12,751,995 B2The Regents of the University of California
- BCMA chimeric antigen receptors6 Oct 2026US 12,752,006 B2Regeneron Pharmaceuticals, Inc.
- Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene6 Oct 2026US 12,752,019 B2Precision BioSciences, Inc.
- Microdystrophin nucleic acid gene therapy constructs and uses thereof6 Oct 2026US 12,752,020 B2REGENXBIO Inc.
- Transgenic model of human cardiomyopathy8 Oct 2026US 2026/0305586 A1Stichting Genetische Hartspierziekte PLN
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Treating a type i interferon upregulation or aberrant il-33 upregulation disease or condition with polyomavirus8 Oct 2026US 2026/0306609 A1The General Hospital Corporation
- Systems and Methods for Delivery of Viral Antigens8 Oct 2026US 2026/0306610 A1Veergen Inc.
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
Most cited
By later US patents
- Mutant dwarfism gene of petunia5,133US 5,523,520 AGoldsmith Seeds, Inc. · 1996
- Recombinant immunoglobin preparations4,785US 4,816,567 AGenentech, Inc. · 1989
- Soybean transformation and regeneration methods2,169US 5,968,830 AMississippi State University · 1999
- Soybean event MON89788 and methods for detection thereof2,074US 7,632,985 B2Monsanto Technology LLC · 2009
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996